Navigation Links
ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
Date:12/11/2007

ignificant unmet need.

Prevention and Treatment of Venous Thromboembolic disease (VTE)

Venous thromboembolic disease (deep vein thrombosis (DVT), pulmonary embolism) represents a major health issue, with an incidence of 1 to 3 per 1000 individuals per year and a high early mortality rate. One of the risk factors for VTE is major orthopaedic surgery. Anticoagulation prophylaxis is therefore indicated in this setting. In addition, in patients who develop a VTE, anticoagulation treatment for at least 6 months is indicated. Therefore, an agent allowing for once-a-month treatment in an outpatient setting is foreseen as an important option for the treatment of VTE.

Stroke Prevention in Atrial Fibrillation (AF)

Atrial fibrillation (AF), which is a strong risk factor for ischemic stroke, is the most common sustained arrhythmia observed in clinical practice. The prevalence of AF is estimated at 0.4% of the general population and increases with age, rising to 8.8% in the group aged 80-89 years. Given the aging population in the U.S. and other developed countries, the overall prevalence of AF is expected to continue to grow over the next several decades.

About ThromboGenics

ThromboGenics is a biotechnology company focused on discovery and development of biopharmaceuticals for the treatment of a range of vascular and eye diseases. The Company has several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases, including acute stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), scheduled to enter Phase II clinical development in 2008, and TB-403 (Anti-PlGF), which is expected to proceed to Phase I clinical trials by the end of 2007. ThromboGenics has built strong links with the University of Leuven
'/>"/>

SOURCE ThromboGenics NV
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
7. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
8. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
9. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
10. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
11. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)... SAN FRANCISCO, Dec. 3 VIA Pharmaceuticals, Inc. (Nasdaq: ... development of compounds for the treatment of cardiovascular and ... last patient visit in its Phase 2 FDG-PET clinical ... 52 patients and was carried out at five sites ...
(Date:12/3/2009)... Inverness Medical Innovations, Inc. (NYSE: IMA ), a ... health at home through the merger of rapid diagnostics and ... on its Series B Convertible Perpetual Preferred Stock ( IMA-PB). ... stock in an amount per share equal to the quotient ...
(Date:12/2/2009)... Md., Dec. 2 Martek Biosciences Corporation (Nasdaq: MATK ... of its fourth quarter and fiscal year 2009 on December ... Following the release, at 4:45 p.m. ET Martek will conduct ... All interested parties may listen to the call live via ...
(Date:12/2/2009)... Dec. 2 Reportlinker.com announces that a ... its catalogue: ,, Carbondioxide Incubators - ... http://www.reportlinker.com/p0164368/Carbondioxide-Incubators---A-Global-Market-Perspective.html ,, Incubators are the ... cancer, research, and other applications for providing ...
Breaking Biology Technology:VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4Martek to Announce Fourth Quarter and Fiscal Year 2009 Results 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 4
... QUEBEC CITY, Nov. 3 /PRNewswire-FirstCall/ - AEterna Zentaris ... biopharmaceutical company focused on,endocrine therapy and oncology, today ... patient recruitment for its Phase 2 trial in ... linked to doxorubicin. The decision to enter the ...
... Halozyme Therapeutics, Inc.,(Nasdaq: HALO ), ... the extracellular matrix, today announced it has ... human hyaluronidase enzyme,(rHuPH20) co-formulations with Humulin(R) R ... lispro) in Type 1 diabetic,patients. This study ...
... Deploys Clustered Storage to Help Redefine the ... Economics of Large-Scale Sequencing, SEATTLE, ... storage, today announced that Complete,Genomics, the world,s first provider of ... of Isilon IQ clustered,storage to unify its vast stores of ...
Other Biology Technology:AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 2AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 3AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 4AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 5Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients 2Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients 3Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients 4Complete Genomics Chooses Isilon IQ to Power World's First Complete Human Genome Sequencing Service 2Complete Genomics Chooses Isilon IQ to Power World's First Complete Human Genome Sequencing Service 3
(Date:12/3/2009)... of this message: , , Preliminary Press ... California Academy of Sciences museum, Attention PIOs: Sending ... registration deadline 10 December, News Media registration ... THIS MONDAY, 7 December, Who,s coming, , ...
(Date:12/3/2009)... Rapids, Mich. (Dec. 3, 2009) Van Andel ... hormone abscisic acid (ABA) works at the molecular level to ... cold. Their findings, published in the journal Nature ... around the world and combat global food shortages. The ...
(Date:12/3/2009)... of the upcoming forest deal at Copenhagen in order to ... University of Leeds. , Writing today in Nature ... the carbon credit payments to be agreed at Copenhagen, known ... made to forest dwellers directly, and their property rights assured. ...
Breaking Biology News(10 mins):AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 2AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 3AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 4AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 5AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 6VAI researchers find long awaited key to creating drought resistant crops 2VAI researchers find long awaited key to creating drought resistant crops 3Forest deal at Copenhagen must avoid creating 'carbon refugees' 2Watson Pharmaceuticals Receives FDA Approval for Generic Toprol XL 28R 29 25 MG and 50 MG 53550 1Watson Pharmaceuticals Receives FDA Approval for Generic Toprol XL 28R 29 25 MG and 50 MG 53550 2Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 1Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 2Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 3Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 4Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 5Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 6Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 7Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 8Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 9Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 10Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 11Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 12Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 13Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 14Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 15ProAssurance Reports Second Quarter 2009 Results 53542 1ProAssurance Reports Second Quarter 2009 Results 53542 2ProAssurance Reports Second Quarter 2009 Results 53542 3ProAssurance Reports Second Quarter 2009 Results 53542 4ProAssurance Reports Second Quarter 2009 Results 53542 5ProAssurance Reports Second Quarter 2009 Results 53542 6ProAssurance Reports Second Quarter 2009 Results 53542 7ProAssurance Reports Second Quarter 2009 Results 53542 8ProAssurance Reports Second Quarter 2009 Results 53542 9ProAssurance Reports Second Quarter 2009 Results 53542 10ProAssurance Reports Second Quarter 2009 Results 53542 11ProAssurance Reports Second Quarter 2009 Results 53542 12ProAssurance Reports Second Quarter 2009 Results 53542 13
... by the University of Colorado at Boulder reveals that ... source of fine, organic particle pollutants that contribute to ... Angeles region. , According to the study, a much ... is directly emitted by vehicles and industrial processes. Instead, ...
... 24, 2008) Self-guided treatment for depression could ... , Scientists with the National Space Biomedical Research ... that will assist astronauts in recognizing and effectively ... pose a substantial threat to crew safety and ...
... release is available in German . , ... and molluscs more than plants. This is the finding of ... Research (UFZ), TU Berlin, the German Federal Institute of Hydrology ... of observations before and after the Elbe floods of August ...
Other Biology News:CU-Boulder study suggests air quality regulations miss key pollutants 2Coming soon: Self-guided, computer-based depression treatment 2Coming soon: Self-guided, computer-based depression treatment 3Vegetation hardly affected by extreme flood events 2
... The FilterMate is a compact, versatile system ... a 96- or 24-well microplates into a ... microplate liquid scintillation and gamma counter. The ... samples for applications such as cell proliferation, ...
... single use spatulas have been designed to ... are for those interested in eliminating the ... Each spatula is individually packaged, RNase/DNase free, ... is a new product number, created to ...
... Progesterone Receptor (PR) Competitor Assay Kits ... novel progesterone receptor binding compounds using ... utilizes a fusion of glutathione transferase ... human progesterone receptor [PR-LBD(GST)] and a ...
... combine the proven features of the pET, ... provides all of the benefits and versatility ... backbone. The pTriEx vectors have been extensively ... in all three expression systems. In each ...
Biology Products: